Interventions for preventing bone disease in kidney transplant recipients-Reference-Cited by-同舟云学术

Interventions for preventing bone disease in kidney transplant recipients

Published:2019-10-22 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Palmer Suetonia C¹,Chung Edmund YM²,McGregor David O³,Bachmann Friederike⁴,Strippoli Giovanni FM⁵⁶⁷⁸

Affiliation:

1. University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140

2. Royal North Shore Hospital; Department of Medicine; 48 Provincial Road Sydney NSW Australia 2070

3. Christchurch Hospital; Department of Nephrology; Private Bag 4710 Christchurch New Zealand 8001

4. Charité University Medicine Berlin; Department of Nephrology and Medical Intensive Care; Charitéplatz 1 Berlin Germany 10117

5. University of Bari; Department of Emergency and Organ Transplantation; Bari Italy

6. Diaverum; Medical Scientific Office; Lund Sweden

7. Diaverum Academy; Bari Italy

8. The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005015.pub4/epdf/full

Reference271 articles.

1. Oral paricalcitol in kidney transplant recipients receiving a corticosteroid-free immunosuppressive regimen: an open label randomized trial [abstract no: LB33];Amer;American Journal of Transplantation,2012

2. Effects of paricalcitol on bone turnover in kidney transplant recipients [abstract no: A39];Amer;Transplantation,2014

3. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial;Amer;American Journal of Transplantation,2013

4. Proteinuria in kidney transplant recipients: prevalence in a national cohort and study design of the effect of paricalcitol for reduction of proteinuria [abstract no: RO-204];Arnol;Transplant International,2011

5. Paricalcitol versus placebo for reduction of proteinuria in kidney transplant recipients: a double-blind, randomized controlled trial [abstract no: 426.4];Arnol;Transplantation,2016

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of bisphosphonate treatment on bone mineral density after kidney transplant;World Journal of Transplantation;2024-09-18

2. Bone health and fracture prevention after kidney transplantation;Journal of Clinical & Translational Endocrinology;2024-06

3. Modern Trends for Primary Hyperparathyroidism: Intervening on Less Biochemically Severe Disease;Journal of Surgical Research;2024-04

4. Efficacy of iguratimod on mineral and bone disorders after kidney transplantation: a preliminary study;Renal Failure;2023-10-31

5. New Human Leukocyte Antigen (HLA) Antibody Formation and Creatinine Elevation With Abaloparatide in Kidney Transplant Recipient;JBMR Plus;2023-09-21